OpenAI leads $153M round pushing Biossil to unicorn status

Toronto-based biotech startup Biossil has crossed the $1 billion valuation mark after raising $153 million in a round led by OpenAI. The funding is intended to support an AI-driven approach to drug development, though details about the pipeline remain limited.

OpenAI’s involvement is the headline here, though its exact role is still emerging. When the firm’s startup fund doubled to $400 million on 30 August, it was positioned to back vertical AI applications, not just horizontal model builders. Biossil appears to fit that thesis: it reportedly applies AI to a specific problem—drug development—rather than building foundation models itself. If this pattern holds, OpenAI may be increasingly acting as both investor and technical partner, embedding its models into portfolio companies’ workflows while taking equity.

The $153 million figure stands out for its size, particularly in biotech, where venture funding often comes in smaller tranches. The round’s scale could suggest investor confidence, though the specifics of Biossil’s business model and progress remain unclear. The company’s focus on AI-assisted drug discovery is a well-trodden space, but OpenAI’s backing may lend it additional visibility.

What remains to be seen is how Biossil will navigate the complexities of drug development, including regulatory and scientific challenges. AI’s role in biotech is still evolving, and even sophisticated models can produce unexpected outcomes, as seen in OpenAI’s own internal incident on 28 September. For Biossil, demonstrating both technical and operational viability will be key.

The round also invites questions about OpenAI’s broader strategy. With an expected IPO on the horizon, the firm may be looking to diversify its revenue streams beyond its core offerings. Investing in vertical AI startups could allow OpenAI to extend its influence without directly building infrastructure in specialized sectors. If this approach gains traction, similar rounds in other industries may follow.

For Biossil, the path forward is uncertain. The company has not yet disclosed partnerships or pilot programs, and its directory listing remains empty. The coming months will reveal whether the funding translates into tangible progress—or whether the round was more about OpenAI’s ambitions than Biossil’s immediate prospects. Either way, the deal reflects a growing trend of AI being applied to niche, high-value problems rather than just scaling models.

Sources: betakit.com